Full text is available at the source.
Abstract
Recent patents reveal new psychedelic compounds optimized for safer and shorter effects.
- These compounds may enhance 5-HTA receptor modulation.
- They could have fewer side effects compared to traditional psychedelics.
- The duration of action may be adjustable to fit clinical needs.
- Refinements involve modifying DMT and psilocin structures through prodrug design and fluorination.
- These advancements aim to improve treatment predictability for psychiatric disorders.
Simplified